Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

Takashi Matsumura; Kenji Tsuchihashi; Takeo Yamamoto; Fumiaki Jinnouchi; Wataru Kusano; Yota Kusumoto; Kohei Arimizu; Hirofumi Ohmura; Yuki Kuma; Shohei Moriyama; Kyoko Yamaguchi; Mamoru Ito; Taichi Isobe; Hiroshi Ariyama; Yoshinao Oda; Koichi Akashi; Eishi Baba

doi:10.2169/internalmedicine.3743-24

Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

Takashi Matsumura
, Kenji Tsuchihashi
, Takeo Yamamoto
, Fumiaki Jinnouchi
, Wataru Kusano
, Yota Kusumoto
, Kohei Arimizu
, Hirofumi Ohmura
, Yuki Kuma
, Shohei Moriyama
, Kyoko Yamaguchi
, Mamoru Ito
, Taichi Isobe
, Hiroshi Ariyama
, Yoshinao Oda
, Koichi Akashi
, Eishi Baba

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.

Original language	English
Pages (from-to)	1728-1732
Number of pages	5
Journal	Internal Medicine
Volume	64
Issue number	11
DOIs	https://doi.org/10.2169/internalmedicine.3743-24
Publication status	Published - 2025

All Science Journal Classification (ASJC) codes

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.3743-24

Cite this

Matsumura, T., Tsuchihashi, K., Yamamoto, T., Jinnouchi, F., Kusano, W., Kusumoto, Y., Arimizu, K., Ohmura, H., Kuma, Y., Moriyama, S., Yamaguchi, K., Ito, M., Isobe, T., Ariyama, H., Oda, Y., Akashi, K., & Baba, E. (2025). Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab. Internal Medicine, 64(11), 1728-1732. https://doi.org/10.2169/internalmedicine.3743-24

Matsumura, T, Tsuchihashi, K , Yamamoto, T , Jinnouchi, F, Kusano, W, Kusumoto, Y, Arimizu, K, Ohmura, H, Kuma, Y, Moriyama, S, Yamaguchi, K , Ito, M , Isobe, T, Ariyama, H, Oda, Y , Akashi, K & Baba, E 2025, 'Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab', Internal Medicine, vol. 64, no. 11, pp. 1728-1732. https://doi.org/10.2169/internalmedicine.3743-24

@article{49c708e1766942b3a11afdf27cf1e516,

title = "Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab",

abstract = "A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.",

keywords = "EBV, immune checkpoint inhibitor, lymph proliferative disorders, pembrolizumab",

author = "Takashi Matsumura and Kenji Tsuchihashi and Takeo Yamamoto and Fumiaki Jinnouchi and Wataru Kusano and Yota Kusumoto and Kohei Arimizu and Hirofumi Ohmura and Yuki Kuma and Shohei Moriyama and Kyoko Yamaguchi and Mamoru Ito and Taichi Isobe and Hiroshi Ariyama and Yoshinao Oda and Koichi Akashi and Eishi Baba",

note = "Publisher Copyright: {\textcopyright} 2025 The Japanese Society of Internal Medicine.",

year = "2025",

doi = "10.2169/internalmedicine.3743-24",

language = "English",

volume = "64",

pages = "1728--1732",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "11",

}

TY - JOUR

T1 - Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

AU - Matsumura, Takashi

AU - Tsuchihashi, Kenji

AU - Yamamoto, Takeo

AU - Jinnouchi, Fumiaki

AU - Kusano, Wataru

AU - Kusumoto, Yota

AU - Arimizu, Kohei

AU - Ohmura, Hirofumi

AU - Kuma, Yuki

AU - Moriyama, Shohei

AU - Yamaguchi, Kyoko

AU - Ito, Mamoru

AU - Isobe, Taichi

AU - Ariyama, Hiroshi

AU - Oda, Yoshinao

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2025

Y1 - 2025

N2 - A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.

AB - A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood. The patient was diagnosed with other iatrogenic immunodeficiency-associated lymph proliferative disorders (OIIA-LPDs) related to EBV activation induced by pembrolizumab. Rituximab was administered, resulting in the improvement of the OIIA-LPD. The emergence of an OIIA-LPD merits close attention in patients receiving immune checkpoint inhibitors.

KW - EBV

KW - immune checkpoint inhibitor

KW - lymph proliferative disorders

KW - pembrolizumab

UR - https://www.scopus.com/pages/publications/105006976985

UR - https://www.scopus.com/pages/publications/105006976985#tab=citedBy

U2 - 10.2169/internalmedicine.3743-24

DO - 10.2169/internalmedicine.3743-24

M3 - Article

C2 - 39428537

AN - SCOPUS:105006976985

SN - 0918-2918

VL - 64

SP - 1728

EP - 1732

JO - Internal Medicine

JF - Internal Medicine

IS - 11

ER -

Lymphoproliferative Disorder in an Esophageal Cancer Patient Treated with Pembrolizumab

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this